Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
about
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDLNovel concepts in HDL pharmacology.A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.High-density lipoprotein-based drug discovery for treatment of atherosclerosis.Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors.
P2860
Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@ast
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@en
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@nl
type
label
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@ast
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@en
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@nl
prefLabel
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@ast
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@en
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@nl
P2093
P2860
P356
P1476
Tolerability, pharmacokinetics ...... nhibitor, in healthy subjects.
@en
P2093
Atsuhiro Kawaguchi
Chisa Suzuki
David Fowler
John J P Kastelein
Koichi Tomiyasu
Matt Lawson
Nobuko Maruyama
Patrick Round
Sander van Deventer
P2860
P304
P356
10.1111/BCP.12380
P407
P577
2014-09-01T00:00:00Z